These companies could innovate their way to success.

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease ...

With a volume of 1,752,912, the price of VRTX is up 1.48% at $439.58. RSI indicators hint that the underlying stock may be ...

Inflation should have a minimal impact on these companies' financial results. And they also boast excellent growth prospects.

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary ...

US biopharma Vertex Pharmaceuticals today announced data from multiple studies demonstrating the clinical benefits of Casgevy ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

On November 18, 2025, ToolGen, Inc. (“ToolGen”) filed a complaint (“Complaint”) in the District of Massachusetts alleging infringement of its ...